A poorly performed biotech stock is a shorters dream. As Tobes mentioned, without a number of substantial agreements we're at the mercy of the market dragging us down (a la Gamestop but without the white knight reddit saviours). The tiny Viraleze sales mentioned in the quarterly is about the same money that your nearest McDonalds store turns over (from a 63 million person locked down country) and there was no other announcements of a partnership with any sector of any kind.
I'm not sure people appreciate just how bad the US VivaGel result was because we have no revenues for the product protecting investors and mitigating the shorters influence.
SPL Price at posting:
$1.66 Sentiment: Hold Disclosure: Held
